(Q46965117)

26 December 2017

title

The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy (English)

1 reference

26 December 2017

chronic lymphocytic leukemia

0 references

0 references

1 reference

1 reference

9

Hagop Kantarjian

1 reference

26 December 2017

10

William G Wierda

1 reference

26 December 2017

2

Susan O'Brien

1 reference

26 December 2017

3

Susan Lerner

1 reference

Apostolia Maria Tsimberidou

26 December 2017

8

object named as

Apostolia M Tsimberidou

1 reference

26 December 2017

Issa F Khouri

4

object named as

I Khouri

1 reference

26 December 2017

Constantine S. Tam

1

object named as

Constantine S Tam

1 reference

26 December 2017

author name string

A Ferrajoli

5

1 reference

26 December 2017

S Faderl

6

1 reference

26 December 2017

M Browning

7

1 reference

26 December 2017

publication date

1 October 2007

1 reference

26 December 2017

published in

Leukemia & Lymphoma

1 reference

26 December 2017

volume

48

1 reference

26 December 2017

issue

10

1 reference

26 December 2017

page(s)

1931-1939

1 reference

26 December 2017

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573257

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573257

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573257

A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573257

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573257

Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573257

Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573257

Alemtuzumab therapy in B-cell lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573257

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573257

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573257

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573257

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573257

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573257

Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573257

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573257

An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573257

Reduced-intensity regimens in allogeneic stem-cell transplantation for non-hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573257

Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573257

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573257

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573257

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573257

10.1080/10428190701573257

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017